Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality

• Published in: Antibiotics (Basel) Vol. 10; no. 11; p. 1296
• Main Authors: de Pablo-Miró, Mar, Pujol-Ruiz, Sergi, Iftimie, Simona, Arenas-Miras, María del Mar, López-Montesinos, Inmaculada, Duran-Jordà, Xavier, Anglès, Albert, Grau, Santiago, Horcajada, Juan P.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 24.10.2021; MDPI
• Subjects: Adverse events; Antibiotics; Antiinfectives and antibacterials; Antimicrobial agents; Bivariate analysis; Clinical outcomes; Comorbidity; Comparative analysis; Compliance; dalbavancin; Daptomycin; effectiveness; Endocarditis; gram-positive; Gram-positive cocci; hospital stay; Hospitalization; Infections; Intravenous administration; Length of stay; Linezolid; Methicillin; Microorganisms; Mortality; Multidrug resistance; multidrug-resistant gram-positive cocci; Patients; Quality of life; Severe acute respiratory syndrome coronavirus 2; Vancomycin
• ISSN: 2079-6382; 2079-6382
• DOI: 10.3390/antibiotics10111296

Dalbavancin is a new antibiotic that is effective against Gram-positive microorganisms, including methicillin-resistant Staphylococci, and offers the possibility of administering intravenous therapy once weekly in an ambulatory setting. We conducted a multicenter observational case-control study, comparing all patients who received dalbavancin (cases) with hospitalized patients who were treated instead with daptomycin, linezolid or vancomycin (controls), based on clinical diagnosis, main microorganism involved, and age. The primary outcome was the length of hospital stay after starting the study antimicrobial. Secondary outcomes were 7-day and 30-day efficacy, 30-day mortality, 90-day recurrence, 90-day and 6-month hospitalization, presence of adverse events and healthcare-associated infections; 161 patients (44 cases and 117 controls) were included. Bivariate analysis showed that dalbavancin reduced the total length of hospital stay (p < 0.001), with fewer 90-day recurrences (p = 0.005), 6-month hospitalizations related to the same infection (p = 0.004) and non-related hospitalizations (p = 0.035). Multivariate analyses showed that length of hospital stay was significantly shorter in patients treated with dalbavancin (−12.05 days 95% CI [−17.00, −7.11], p < 0.001), and 30-day efficacy was higher in the dalbavancin group (OR 2.62 95% CI [1.07, 6.37], p = 0.034). Although sample size of the study may be a limitation, we can conclude that Dalbavancin is a useful antimicrobial drug against Gram-positive infections, including multidrug-resistant pathogens, and allows for a remarkable reduction in length of hospital stay with greater 30-day efficacy.